Manufacturing

Kriya has gene therapy vial filling capabilities

Kriya’s Manufacturing, Product Design, and Research & Development (R&D) capabilities are closely integrated into a unified gene therapy product engine, empowering us to create transformational adeno-associated virus (AAV)-based gene therapies for common diseases.

World-Class Gene Therapy Manufacturing

Kriya’s in-house, large-scale GMP manufacturing facilities for gene therapy are integral to our success, helping to turn our vision into reality.

Kriya’s vial filling machine for gene therapy products
Kriya has an in-house large-scale GMP manufacturing facility
Kriya has in-house Akta chromatography purification system
Kriya has gene therapy analytical testing capabilities
Kriya has gene therapy manufacturing capabilities

Our manufacturing headquarters is strategically located in Research Triangle Park, North Carolina, a global center of biologics manufacturing.

Our facility provides multi-product manufacturing capabilities ranging from 1L lab scale up to 3,000L bioreactor scale. We have GMP production capacity of 50L, 500L and 3,000L.

Kriya world-class GMP manufacturing site in the heart of Research Triangle Park North Carolina.

Our industry-leading expertise in AAV gene therapy manufacturing provides the following strategic advantages:

Integrated manufacturing accelerates product development

  • Manufacturing is integrated with each stage of development – including vector design optimization for product quality and manufacturability – to maintain high quality, consistency, and scalability throughout the product life cycle
  • Our in-house platform manufacturing process utilizes the same series of unit operations from research-scale to commercial-scale production, enabling seamless scale-up to support gene therapy clinical trials, avoiding costly process changes, and decreasing time-to-market

In-house analytical capabilities and innovative manufacturing processes enable industry-leading product quality with higher productivity and lower costs

  • We prioritize achieving industry-leading product quality by conducting extensive, in-house analytical characterization and optimization of critical quality attributes starting early in product development
  • Our innovative gene therapy manufacturing processes and technologies optimize upstream volumetric productivity and downstream yield to reduce overall cost

GMP production at scale enables clinical trials and future commercialization of products

  • Our multi-product platform process is designed to manufacture any AAV serotype, with GMP production from 50L, 500L and 3,000L scale, internal fill/finish, and quality-control testing and release
  • We have active GMP manufacturing operations ongoing, with multiple large-scale campaigns across several pipeline programs

Back to Top